Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal ...
Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; ...
Acute leukemia is a group of hematologic malignancies categorized according to the immature cells that proliferate and replace the normal bone marrow. Flow cytometry has emerged as a cornerstone in ...
SAN DIEGO, Sept. 27, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine predictive biomarker approach to develop drugs that ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...
Leukemia is a type of cancer that impacts cells in the bone marrow. There are several types of leukemia. Acute myeloid leukemia (AML) is one of them. While AML mostly affects older adults, younger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback